Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer

被引：3
|
作者：
Classe, J. -M. [1 ]
Muller, M. [2 ]
Frenel, J. -S. [3 ]
Rigaud, D. Berton [3 ]
Ferron, G. [4 ]
Jaffre, I. [1 ]
Gladieff, L. [5 ]
机构：
[1] Ctr Rene Gauducheau, Dept Chirurg Oncol, F-44805 St Herblain, France
[2] CHU Nantes, Dept Chirurg Oncol, F-44 Nantes, France
[3] Ctr Rene Gauducheau, Dept Med Oncol, F-44805 St Herblain, France
[4] Inst Claudius Regaud, Dept Chirurg Oncol, Toulouse, France
[5] Inst Claudius Regaud, Dept Med Oncol, Toulouse, France
来源：
JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION | 2010年 / 39卷 / 03期
关键词：
Advanced ovarian cancer; Intraperitoneal chemotherapy; Hyperthermic intraperitoneal chemotherapy; HYPERTHERMIC PERITONEAL PERFUSION; HIGH-DOSE CARBOPLATIN; CYTOREDUCTIVE SURGERY; COMPLETE RESECTION; CARCINOMA PATIENTS; PHASE-II; CISPLATIN; RECURRENT; THERAPY; PACLITAXEL;
D O I：
10.1016/j.jgyn.2009.12.007
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
The standard treatment for advanced ovarian cancer consist in complete surgical debulking and intravenous platin and taxane based chemotherapy. Despite research efforts, a lot of patients still die from peritoneal carcinomatosis. The aim of our work was to present the state of art about intraperitoneal chemotherapy. Intraperitoneal chemotherapy (IPC): three multi-institutional randomised trials showed that platin based IPC gave better results in term of overall and disease free survival when compared to standard intravenous treatment. Even so, IPC is not yet becoming a new international standard of treatment because a high rate of morbidity. Hyperthermic Intraperitoneal chemotherapy (HIPEC) represents an innovative alternative to IPC. HIPEC is based on a complete surgical debulking without any visible mass and an intraperitoneal chemotherapy with synergy of hyperthermia. Phase II trails have shown its feasibility. Randomised trials are needed to assess its efficiency in improving survival. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：183 / 190
页数：8
相关论文
共 50 条
  • [41] THE USE OF INTRAPERITONEAL CHEMOTHERAPY IN THE TREATMENT OF OVARIAN-CANCER
    MYERS, C
    SEMINARS IN ONCOLOGY, 1984, 11 (03) : 275 - 284
  • [42] Is neoadjuvant chemotherapy feasible prior to intraperitoneal chemotherapy in women with advanced ovarian cancer?
    Barnett, G.
    Rogers, A.
    Robinson, W.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 366 - 366
  • [43] Survival and adverse treatment effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced stage ovarian cancer
    Potkonjak, Ana-Meyra
    Vranes, Hrvojka Soljacic
    Vukovic, Ante
    Tuckar, Neven
    Butorac, Drazan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A397 - A398
  • [44] Intraperitoneal chemotherapy for ovarian cancer
    Ozols, RF
    Bookman, MA
    Young, RC
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (15): : 1641 - 1642
  • [45] Intraperitoneal Chemotherapy for Ovarian Cancer
    Anastasia, Paula
    ONCOLOGY NURSING FORUM, 2012, 39 (04) : 346 - 348
  • [46] Intraperitoneal chemotherapy of ovarian cancer
    Lowe, Thomas
    Morgan, Robert J.
    WOMENS HEALTH, 2007, 3 (04) : 433 - 440
  • [47] Intraperitoneal chemotherapy for ovarian cancer
    Gregory Friberg
    Gini Fleming
    Current Oncology Reports, 2003, 5 (6) : 447 - 453
  • [48] Intraperitoneal chemotherapy in ovarian cancer
    Delemer-Lefebvre, M.
    Ascencio, M.
    Cottu, P. -H.
    Villet, R.
    Vinatier, D.
    Collinet, P.
    GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2007, 35 (09): : 791 - 796
  • [49] Intraperitoneal chemotherapy in ovarian cancer
    Hofstra, LS
    de Vries, EGE
    Mulder, NH
    Willemse, PHB
    CANCER TREATMENT REVIEWS, 2000, 26 (02) : 133 - 143
  • [50] Intraperitoneal chemotherapy for ovarian cancer
    Hamilton, Chad A.
    Berek, Jonathan S.
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (05) : 507 - 515
12345